Immunomic Therapeutics is pleased to announce the expansion of its technology platform, now called UNITE — or UNiversal Intracellular Targeted Expression.
In 2006, the company licensed its foundational investigational LAMP-Vax technology from Johns Hopkins University. Since then, the research program has evolved through partnerships, internal R&D, and the addition of new tools and methods that have the potential to amplify the immune response. This work gave rise to a pipeline of pre-clinical and clinical programs, protected by a wealth of new patent applications. None of this would have been possible without LAMP-Vax science, but the company believes that UNITE better describes the deep, multifaceted platform that exists today.
UNITE brings together a series of intracellular and molecular biological methods for enhanced MHC-II presentation. Coupled with potent adjuvants and delivery technologies, the resulting vaccines have the potential to harness the body’s natural biochemistry to generate a broad immune response.
By encouraging antibody production, cytokine release, critical immunological memory and more, the company hopes to bring the benefits of immunotherapy to hard-to-treat cancers and individual non-responders. For example, one UNITE vaccine candidate is currently being studied in a Phase II clinical trial for patients with glioblastoma multiforme (GBM), a deadly brain cancer that has thus far evaded immunotherapy treatment approaches. With partner Astellas Pharmaceuticals, UNITE vaccines are also being studied as a preventive tool for treating allergic diseases.
An impressive amount of progress and diversification has happened over the last 12 years. That is now being recognized with the name change to UNITE. But regardless of what acronym is used, it’s safe to say there is a lot of potential in the science.
For more information about Immunomic’s technology visit https://www.immunomix.com/unite/.